A Phase I Clinical Study to Evaluate the Safety, Tolerability, & Efficacy

Clinical Trial Summary

This study is a prospective, single-arm, open-label, single-dose dose finding and extension study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the LCAR-M23 CAR-T cell therapy in subjects with relapsed and refractory epithelial ovarian cancer after prior adequate standard of care.

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03393884` - Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)	Phase 1/Phase 2
Recruiting	`NCT05200559` - T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04546373` - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting	`NCT03371693` - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer	Phase 3
Completed	`NCT01442051` - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer	N/A
Not yet recruiting	`NCT04983550` - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC	Phase 2
Completed	`NCT02480374` - Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer	Phase 1
Recruiting	`NCT01680575` - Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer	N/A
Terminated	`NCT01202890` - Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer	Phase 1
Completed	`NCT00561795` - Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors	Phase 2
Completed	`NCT00314678` - Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer	Phase 2
Recruiting	`NCT05212779` - Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Recruiting	`NCT04620954` - Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin	Phase 1/Phase 2
Completed	`NCT02312661` - Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer	Phase 1
Completed	`NCT01666444` - VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 2
Completed	`NCT01891344` - A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)	Phase 2
Recruiting	`NCT04516447` - A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer	Phase 1
Terminated	`NCT02943317` - Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer	Phase 1
Active, not recruiting	`NCT01447706` - A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers	Phase 2
Active, not recruiting	`NCT01276574` - Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT

NCT number	NCT04562298
Study type	Interventional
Source	Shanghai East Hospital
Contact
Status	Terminated
Phase	Phase 1
Start date	October 21, 2020
Completion date	June 7, 2022

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms